Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity - PubMed (original) (raw)
Clinical Trial
. 2004 Jan 15;103(2):383-9.
doi: 10.1182/blood-2003-04-1155. Epub 2003 Sep 25.
Affiliations
- PMID: 14512316
- DOI: 10.1182/blood-2003-04-1155
Free article
Clinical Trial
Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity
Mie Nieda et al. Blood. 2004.
Free article
Abstract
Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells. Preclinical models show that activation of Valpha24+Vbeta11+ NKT cells induces effective antitumor immune responses and potentially important secondary immune effects, including activation of conventional T cells and NK cells. We describe the first clinical trial of cancer immune therapy with alpha-GalCer-pulsed CD1d-expressing dendritic cells. The results show that this therapy has substantial, rapid, and highly reproducible specific effects on Valpha24+Vbeta11+ NKT cells and provide the first human in vivo evidence that Valpha24+Vbeta11+ NKT cell stimulation leads to activation of both innate and acquired immunity, resulting in modulation of NK, T-, and B-cell numbers and increased serum interferon-gamma. We present the first clinical evidence that Valpha24+Vbeta11+ NKT cell memory produces faster, more vigorous secondary immune responses by innate and acquired immunity upon restimulation.
Similar articles
- Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.
van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, Pinedo HM, Scheper RJ, Giaccone G. van der Vliet HJ, et al. J Immunol Methods. 2001 Jan 1;247(1-2):61-72. doi: 10.1016/s0022-1759(00)00272-6. J Immunol Methods. 2001. PMID: 11150537 - Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.
van der Vliet HJ, Molling JW, von Blomberg BM, Kölgen W, Stam AG, de Gruijl TD, Mulder CJ, Janssen HL, Nishi N, van den Eertwegh AJ, Scheper RJ, van Nieuwkerk CJ. van der Vliet HJ, et al. Clin Immunol. 2005 Feb;114(2):183-9. doi: 10.1016/j.clim.2004.10.001. Clin Immunol. 2005. PMID: 15639652 - Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells.
van der Vliet HJ, Molling JW, Nishi N, Masterson AJ, Kölgen W, Porcelli SA, van den Eertwegh AJ, von Blomberg BM, Pinedo HM, Giaccone G, Scheper RJ. van der Vliet HJ, et al. Cancer Res. 2003 Jul 15;63(14):4101-6. Cancer Res. 2003. PMID: 12874013 - Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L. Van Kaer L. Immunol Res. 2004;30(2):139-53. doi: 10.1385/IR:30:2:139. Immunol Res. 2004. PMID: 15477656 Review. - Application of natural killer T cells in antitumor immunotherapy.
Hong C, Park SH. Hong C, et al. Crit Rev Immunol. 2007;27(6):511-25. doi: 10.1615/critrevimmunol.v27.i6.20. Crit Rev Immunol. 2007. PMID: 18197797 Review.
Cited by
- Contradictory Effect of Lymphocyte Therapy and Prednisolone Therapy on CD3+CD8+CD56+ Natural Killer T Population in Women with Recurrent Spontaneous Abortion.
Rezayat F, Esmaeil N, Rezaei A, Sherkat R. Rezayat F, et al. J Hum Reprod Sci. 2023 Jul-Sep;16(3):246-256. doi: 10.4103/jhrs.jhrs_8_23. Epub 2023 Sep 29. J Hum Reprod Sci. 2023. PMID: 38045499 Free PMC article. - An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo.
Tsuji M, Nair MS, Masuda K, Castagna C, Chong Z, Darling TL, Seehra K, Hwang Y, Ribeiro ÁL, Ferreira GM, Corredor L, Coelho-Dos-Reis JGA, Tsuji Y, Mori M, Boon ACM, Diamond MS, Huang Y, Ho DD. Tsuji M, et al. Nat Commun. 2023 Jul 5;14(1):3959. doi: 10.1038/s41467-023-39738-1. Nat Commun. 2023. PMID: 37402814 Free PMC article. - A Lysosome-Targeted Tetrazine for Organelle-Specific Click-to-Release Chemistry in Antigen Presenting Cells.
Ligthart NAM, de Geus MAR, van de Plassche MAT, Torres García D, Isendoorn MME, Reinalda L, Ofman D, van Leeuwen T, van Kasteren SI. Ligthart NAM, et al. J Am Chem Soc. 2023 Jun 14;145(23):12630-12640. doi: 10.1021/jacs.3c02139. Epub 2023 Jun 3. J Am Chem Soc. 2023. PMID: 37269296 Free PMC article. - A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.
Dasyam N, Sharples KJ, Barrow C, Huang Y, Bauer E, Mester B, Wood CE, Authier-Hall A, Dzhelali M, Ostapowicz T, Kumar R, Lowe J, Maxwell A, Burn OK, Williams GM, Carley SE, Caygill G, Jones J, Chan STS, Hinder VA, Macapagal J, McCusker M, Weinkove R, Brimble MA, Painter GF, Findlay MP, Dunbar PR, Gasser O, Hermans IF. Dasyam N, et al. Cancer Immunol Immunother. 2023 Jul;72(7):2267-2282. doi: 10.1007/s00262-023-03400-y. Epub 2023 Mar 7. Cancer Immunol Immunother. 2023. PMID: 36881133 Free PMC article. Clinical Trial. - Augmenting Granzyme B-Expressing NK Cells by Invariant NKT Ligand-Loaded APCs in Patients with Postoperative Early Stage Non-Small Cell Lung Cancer: Results of a Randomized Phase II Study.
Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K, Mushiroda T, Saka H, Kitagawa C, Shimamatsu SI, Takenoyama M, Suehiro Y, Imai T, Shintani A, Ito S, Fujii SI. Iyoda T, et al. Immunohorizons. 2023 Jan 1;7(1):1-16. doi: 10.4049/immunohorizons.2200091. Immunohorizons. 2023. PMID: 36637516 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources